Here are the 10-K annual reports from Cassava Sciences, Inc. (SAVA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SAVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SAVA filings page.
Filana Therapeutics, Inc. (formerly Cassava Sciences) is a clinical-stage biotech focused on simufilam, an oral small molecule targeting the filamin A protein to treat Tuberous Sclerosis Complex (TSC)-related epilepsy and other CNS disorders. The company has discontinued all Alzheimer’s disease trials after two large Phase 3 studies failed to meet pre-specified efficacy endpoints, though simufilam showed a favorable safety profile in over 2,000 treated patients.
Filana holds a broad patent portfolio on simufilam through at least 2029–2040 and, in February 2025, licensed additional worldwide rights from Yale University, agreeing to up to $4.5 million in milestones plus low- to mid-single digit royalties and minimum annual payments. Preclinical work in multiple mouse models suggests simufilam may reduce seizure activity in TSC-related epilepsy.
The company filed an IND to start a proof-of-concept TSC epilepsy trial, but the FDA placed the proposed study on full clinical hold on December 15, 2025, pending more preclinical data and protocol changes, delaying clinical timelines. Research and development expenses declined to $26.6 million in 2025 from $69.6 million in 2024 and $89.4 million in 2023 as Alzheimer’s and SavaDx programs were wound down. Management highlights substantial development, regulatory, funding, and litigation risks, and explicitly warns that investors must be prepared for the possibility of a total loss of capital.